T1	Intervention 0 151	Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial
T2	Intervention 564 845	A total of 136 antiretroviral-naïve patients, with a CD4 cell count above 100 cells/microL and a plasma HIV RNA below 100,000 HIV-1 RNA copies/mL, were randomized and dosed with either lopinavir/ritonavir monotherapy (n = 83) or lopinavir/ritonavir + zidovudine/lamivudine (n = 53)
T3	Intervention 1460 1607	To week 96, a total of 28 patients (34%) had discontinued the study treatment. In addition, the allocated treatment was changed for seven patients.
T4	Intervention 409 440	lopinavir/ritonavir monotherapy
T5	Intervention 444 521	triple combination therapy with zidovudine/lamivudine and lopinavir/ritonavir
